Company news

Recce Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Phase I Clinical Trial Data Review Complete

July 19, 2023

A$801,604 R&D Rebate Advance Received

July 12, 2023

First Cohort Dosed in Rapid Infusion Phase I/II UTI study

July 10, 2023

Ethics Approval for Phase I/II UTI Trial Expansion

June 29, 2023

Ethics Approval to Start Phase I/II (I.V.) Clinical Trial

April 17, 2023

New Family 4 Patent to be Granted for RECCE Anti-Infectives

April 10, 2023

Recce Receives Further A$973,144 R&D Advance

April 4, 2023

Corporate Presentation - WI Emergence 2023

March 22, 2023

Recce Selects CMAX for Phase I/II UTI Clinical Trial

February 19, 2023

A$6.21m Received from R&D Rebate Payments

January 24, 2023

JP Morgan Healthcare Conference

January 10, 2023

Australian Patent to be Granted for RECCE Anti-Infectives

January 9, 2023

Anti-Infective Research Unit est. at Murdoch Childrens

December 15, 2022

Approval to Start Phase I/II Diabetic Foot Ulcer Study

December 8, 2022

Anti-Infective Portfolio Update and Webinar details

October 18, 2022

Pause in trading

October 17, 2022

R327 COVID Study Update

October 17, 2022

Expansion and Acceleration of Clinical Programs

September 27, 2022

Appendix 4E

August 31, 2022

Phase I Clinical Trial of R327 I.V. - 6000mg Complete

August 21, 2022

Corporate Presentation - Aussie Equities Day 2022

July 28, 2022

Phase I Positive Safety Data - 4000mg Complete

June 21, 2022

Phase I Clinical Trial R327 Advances to 4000mg

May 20, 2022

Corporate Presentation - Biotech Investor Lunch

May 16, 2022

Phase I Clinical Trial R327 Advances to High Dose Cohort

April 12, 2022

Anti-Viral Patent Granted in Hong Kong

April 11, 2022

Positive safety data from 4th Cohort -Phase I Clinical Trial

March 29, 2022

$3.08m R&D Rebate Received

March 28, 2022

Safety Committee Clears PhI R327 Dose Increase

March 6, 2022

S&P DJI Announces March 2022 Quarterly Rebalance

March 4, 2022

Positive Safety Continues in 3rd Cohort PhI Clinical Trial

February 20, 2022

Positive Safety Data from Third Cohort of PI Clinical Trial

February 7, 2022

Positive Safety Data from Second Cohort of PI Clinical Trial

January 18, 2022

Positive Safety Data from Phase 1 Clinical Trial

January 6, 2022

Patients to be Dosed in Ph 1 IV Clinical Trial of R327

December 14, 2021

Update on Phase I/II Clinical Trial for Burn Wound Infection

December 6, 2021

Appendix 4C and Activity Report

October 29, 2021

Ethics Approval to Start Phase 1 Intravenous Clinical Trial

October 24, 2021

Reinstatement to Official Quotation

October 12, 2021

Court Orders Granted

October 11, 2021

Suspension from Official Quotation

October 11, 2021

Trading halt

October 8, 2021

R327 Phase I Clinical Trial Registered on ANZCTR

September 30, 2021

Recce Receives Further Innovation Connections Grant

August 11, 2021

Anti-Viral Patent Granted in USA for RECCE Anti-Infectives

July 22, 2021

Anti-Viral Patent Granted in China

July 20, 2021

Outstanding Efficacy Against Flesh-Eating Bacteria

July 19, 2021

Multiple Patients Dosed in Topical Phase I/II Clinical Trial

July 11, 2021

Recce Clinical Pipeline Update

June 7, 2021

R327 Demonstrates World First Multiple Mechanisms of Action

May 27, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 26 decks. Every deck is listed under its year.